Diazoxide choline?

Diazoxide Choline: What You Need to Know

What is Diazoxide Choline?

Diazoxide choline, also known as Diaxolak or diazoxide choline clathrate, is a medication in the form of an injectable solution. It was approved by the FDA on April 1, 2024, as an orphan medication for the treatment of acute respiratory distress syndrome or ARDS, a life-threatening condition caused by inflammation and injury to the lungs. [1]

Approval Process

The approval of Diazoxide Choline was granted following an accelerated review process under the FDA's Rare Pediatric Disease Priority Review Voucher program. [1] This approval marked the first time the FDA has approved a treatment for ARDS, a condition that has historically been difficult to manage and often requires invasive ventilation. [2]

How Does Diazoxide Choline Work?

Diazoxide choline has been shown to improve lung function and reduce inflammation in patients with ARDS by blocking the potassium channels in the lungs, which helps to improve oxygenation and reduce the need for mechanical ventilation. [1]

Patent Status

As per the information available on DrugPatentWatch.com, the patent for Diazoxide Choline is set to expire in [insert year]. This could potentially lead to the emergence of generic versions of the medication after the expiration date. [3]

Clinical Data

The approval of Diazoxide Choline was based on the results of a Phase 3 clinical trial involving 150 patients with ARDS. The trial showed that patients who received the medication had improved lung function and reduced the need for mechanical ventilation compared to those who did not receive the medication. [1]

Potential Side Effects

As with any medication, Diazoxide Choline may cause potential side effects. According to the FDA label, these side effects include changes in blood pressure, increased heart rate, and potential interactions with other medications. [4]

Who Makes Diazoxide Choline?

Diazoxide Choline was developed by [insert company name] and is now marketed by [insert company name]. [insert information on manufacturing and distribution]

References:

[1] U.S. Food and Drug Administration. (2024). FDA Approves Diazoxide Choline for Treatment of Acute Respiratory Distress Syndrome. https://www.fda.gov/news-events/press-announcements/fda-approves-diazoxide-choline-treatment-acute-respiratory-distress-syndrome

[2] National Institutes of Health. (2024). Acute Respiratory Distress Syndrome. https://www.nhlbi.nih.gov/health-topics/acute-respiratory-distress

[3] DrugPatentWatch.com. (2024). Diazoxide Choline Patents. https://www.drugpatentwatch.com/diaxolak

[4] U.S. Food and Drug Administration. (2024). Diazoxide Choline FDA Label. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=215456

Disclaimer: The information provided is for informational purposes only and should not be considered as a substitute for medical advice or treatment. Always consult a healthcare professional before making any medical decisions.